Related Experiment Videos
Modelling of the ischemic penumbra
O Kempski1, T Seiwert, H Otsuka
1Institute for Neurosurgical Pathophysiology, Johannes Gutenberg-University Mainz, Germany.
Acta Neurochirurgica. Supplement
|September 24, 1999
Summary
New rat models offer distinct advantages for studying the ischemic penumbra, the area around a stroke core. These models help investigate mechanisms transforming penumbra into necrotic tissue and evaluate therapeutic approaches for stroke outcome.
Area of Science:
- Neuroscience
- Cerebrovascular Research
- Stroke Pathophysiology
Background:
- The ischemic penumbra's fate critically influences stroke outcomes.
- Current research predominantly uses middle cerebral artery occlusion rat models.
- Understanding penumbra pathophysiology is key to developing effective stroke therapies.
Purpose of the Study:
- To introduce two novel rat models for studying ischemic penumbra pathophysiology.
- To provide models suitable for investigating mechanisms of penumbra-to-infarct transformation.
- To enable evaluation of therapeutic strategies targeting stroke progression.
Main Methods:
- Model 1: Carotid artery occlusion combined with hypobaric hypotension (50 mm Hg) to induce critical cortical flow reduction without an infarct core.
- Cortical blood flow assessment using laser Doppler scanning.
- Model 2: Photochemical occlusion of adjacent cortical veins, leading to widespread cortical flow reduction and small infarcts (2-5 mm³).
Main Results:
- Model 1 creates a large penumbra territory amenable to studying mediator mechanisms.
- Model 2 facilitates the study of infarct growth by mediator administration and therapeutic interventions.
- Both models allow for the evaluation of pathophysiologic significance of individual mediator mechanisms.
Conclusions:
- The proposed rat models offer distinct advantages over existing methods for studying the ischemic penumbra.
- These models are valuable tools for dissecting the mechanisms of ischemic tissue damage after stroke.
- They provide a platform for testing novel therapeutic approaches to improve stroke outcomes.